- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Nicole Rosendale: Data Lagging in Neurologic Care for LGBTQ+ Individuals
Nicole Rosendale, MD, assistant professor of neurology at the University of California San Francisco, neurologist/neurohospitalist, discusses how many unknowns prevail in data concerning neurologic care for LGBTQ+ individuals.
Multiple unknowns are still present in data among LGBTQ+ individuals seeking neurologic care, says Nicole Rosendale, MD, assistant professor of neurology at the University of California San Francisco, neurologist/neurohospitalist.
Transcript
What are some of the greatest health-related neurological needs in the LGBTQ+ community?
I think this is a really important question and one where, unfortunately, we don't have a great answer at this point in time. There's certainly a lot more research that needs to be done. The challenge right now is that because data sources are so limited, not everyone is asking folks their sexual orientation or gender identity in a systematic way. There's a lot that we don't know. I was able to do a scoping review that was published in 2021 that tried to summarize a little bit of the current science of LGBTQ health in neurology, and there was a suggestion that there are certain disparities, particularly in terms of prevalence of certain conditions, such as stroke, for example, and conditions such as functional neurologic disorders, potentially, but there's many, many answers that we don't know and many areas of neurology that still need coverage.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
